Swarajya Logo
  • Morning Brief
  • States
  • Politics
  • Economy
  • Business
  • Culture
  • Infra
  • Defence
  • World
  • Books
  • Ideas
  • Science
  • Technology
  • Heritage
  • Archives
  • Our Views
  • Magazine
  • Headlines
  • Store

Gilead Sciences Inc

Coronavirus: US Planning To Treat Severely Sick Covid-19 Patients With Remdesivir

IANS
5y Insta
image

Covid-19: Gilead’s Antiviral Drug Remdesivir Said To Have Flopped In First Clinical Trial But Company Disputes Results

Swarajya Staff
5y Insta
image

Shares Of Gilead Sciences Surge After Clinical Trial Suggest That  Remdesivir Helped Covid-19 Patients Recover Quickly

Swarajya Staff
5y Insta
image

Remdesivir: Two-Thirds of Severe Coronavirus Patients Improved After Receiving The Drug During A Limited Trial 

Swarajya Staff
5y Insta
image

Three Coronavirus Vaccine Candidates That Show Promise

Swarajya Videos
5y Videos
image

Gilead Sciences Commences Clinical Trial Of Remdesivir, The Most Promising Antiviral Drug So Far To Treat Coronavirus

Swarajya Staff
5y News Brief
image

Get Swarajya in your inbox.


About Swarajya

Shaping the modern Indian's worldview, speaking on behalf of those invested in the cultural and economic prosperity of India. Published since 1956.


Swarajya is a publication by Kovai Media Private Limited.

editor@swarajyamag.com

Useful Links

  • About Us
  • Subscriptions Support
  • Editorial Philosophy
  • Press Kit
  • Privacy Policy
  • Terms of Use
  • Code of Conduct
  • Plagiarism Policy
  • Refund & Cancellation Policy

Useful Links

  • About Us
  • Subscriptions Support
  • Editorial Philosophy
  • Press Kit
  • Privacy Policy
  • Terms of Use
  • Code of Conduct
  • Plagiarism Policy
  • Refund & Cancellation Policy

Participate

  • Contact Us
  • Write for us
  • Style Guide
  • Jobs

Stay Connected

  • Artboard 2 Copy 6Created with Sketch.
    Artboard 2 Copy 10Created with Sketch.
    Artboard 2 Copy 7Created with Sketch.
    Artboard 2 Copy 9Created with Sketch.
  • Andriod Logo
  • IOS Logo